Department of Biomedical Sciences, Humanitas University, Milan 20072, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan 20089, Italy.
World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. doi: 10.3748/wjg.v30.i9.1253.
Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.
乙型肝炎病毒（HBV）再激活（HBVr）是一种严重且可能危及生命的病症，可以通过血液检测筛查或预防性治疗来预防。HBVr 的评估传统上考虑了 HBV 谱等因素，包括乙型肝炎表面抗原（HBsAg）和乙型肝炎核心抗原抗体，以及药物类型（化疗；免疫调节剂）。然而，考虑到患者潜在的肿瘤以及具体的恶性肿瘤类型（实体瘤或血液瘤）也起着至关重要的作用，需要对其进行评估以做出决策。
